The company operates two multi-specialty hospitals in the Junagadh and Veraval regions of Gujarat, providing primary, secondary, and tertiary medical care alongside an integrated pharmacy and pathology laboratory.
The company lacks a structural moat, as evidenced by its small scale and reliance on government-sponsored schemes like PMJAY, which typically limit pricing power. While local geographic presence provides some convenience, the low ROE and stagnant EPS despite massive revenue growth suggest no sustainable competitive advantage.
The company recently raised significant capital through an IPO, primarily for hospital expansion. However, historical capital deployment has resulted in stagnant EPS despite a 110% revenue CAGR, indicating poor incremental returns on invested capital.
The company's aggressive expansion, funded by IPO proceeds, failed to translate into shareholder value as incremental returns on capital collapsed. Despite massive top-line growth, the lack of an internal audit system and weak financial controls allowed operational inefficiencies and related-party leakages to erode margins. The business remained a captive of low-margin government schemes, and without pricing power or a structural moat, it eventually buckled under the weight of its own overhead, leaving investors with stagnant earnings and a permanently impaired share price.
RichFakir rates Sangani Hospitals Ltd's business quality as poor — 33/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Sangani Hospitals Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Sangani Hospitals Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Sangani Hospitals Ltd's fair value is about ₹19 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →